Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.38 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | ROS1 | P08922 | 1/20 | 0.38 |
| ▸ | FER | P16591 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092597 | 0.93 | ALDH1A1 (0.43) | FGFR1KDRCLK2HIPK4SRPK1 | |
| SCHEMBL2091072 | 0.91 | MET (0.42) | FGFR1KDRCLK2HIPK4SRPK1 | |
| SCHEMBL2092399 | 0.89 | ALDH1A1 (0.45) | FGFR1KDRCLK2HIPK4SRPK1 | |
| SCHEMBL2093412 | 0.88 | ABL1 (0.52) | NPC1TP53RAB9AABL1 | |
| SCHEMBL2096491 | 0.87 | ADORA3 (0.46) | FGFR1KDRCLK2HIPK4SRPK1 | |
| SCHEMBL2091667 | 0.86 | NPC1 (0.52) | GRM5NPC1TP53RAB9AGAA | |
| SCHEMBL2093770 | 0.86 | F10 (0.45) | NPC1TP53RAB9AF10ALDH1A1 | |
| SCHEMBL2092674 | 0.86 | ABL1 (0.48) | NPC1TP53RAB9AABL1 | |
| SCHEMBL2093370 | 0.86 | DEGS1 (0.45) | FGFR1GRM5NPC1TP53RAB9A | |
| SCHEMBL2095105 | 0.86 | MEN1 (0.48) | FGFR1GRM5NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2004626-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | NLRP3, CXCR1, CXCR2 | FGFR1 309/4885KDR 3373/4885CLK2 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.